Skip to Content

Join the 'Juxtapid' group to help and get support from people like you.

Juxtapid News

Heart Disease Doesn't Take a Holiday

Posted 25 Nov 2015 by

WEDNESDAY, Nov. 25, 2015 – People with heart disease should take a number of precautions if they travel over the Thanksgiving holiday, an expert suggests. The first step is to be as well-prepared on your trip as you are at home, said Dr. Winston Gandy Jr., a cardiologist at Piedmont Heart Institute in Atlanta. "Make sure when you travel that you have your medicine," Gandy said in an American Heart Association news release. Some people carry a copy of their original prescriptions in case they lose their medications, but having a list of your medications and your cardiologist's phone number should be sufficient. It's also a good idea to tell your cardiologist where you'll be. "Chances are your cardiologist is going to know someone there, either personally or by reputation," who can provide you with help if needed, Gandy said. Research medical facilities at your destination, and know what ... Read more

Related support groups: Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Niacin, Zocor, Niaspan, Azor, Lovastatin, Benicar HCT, Exforge, Diovan HCT, Hyzaar, Rosuvastatin, Lotrel, Avalide, Pravachol, Livalo, Hydrochlorothiazide/Lisinopril

One-Third of Americans Have Dangerous Mix of Heart Risk Factors

Posted 19 May 2015 by

TUESDAY, May 19, 2015 – More than one-third of U.S. adults have a combination of health problems collectively known as metabolic syndrome that increase the risk of heart disease and diabetes, according to new research. What's worse, the researchers found the rate of metabolic syndrome increases dramatically with age. Almost half of people 60 or older in the United States have metabolic syndrome, the study found. "That's concerning, because we know the population of the U.S. is aging," said senior author Dr. Robert Wong, an assistant clinical professor at University of California, San Francisco. "I think it will potentially place a huge burden on our health care system." Metabolic syndrome is a "perfect storm" of conditions that include high blood pressure, abnormal cholesterol levels, increased levels of blood sugar, and a wider waist circumference, Wong said. Medical experts are ... Read more

Related support groups: High Blood Pressure, Diabetes, Type 2, Hypertension, Heart Disease, High Cholesterol, Lipitor, Simvastatin, Crestor, Atorvastatin, Pravastatin, Angina, Niacin, Insulin Resistance, Zocor, Niaspan, Lovastatin, Pre-Diabetes, Vytorin, Rosuvastatin, Hypertriglyceridemia

New Drug Class Slashes 'Bad' Cholesterol, Review Finds

Posted 27 Apr 2015 by

MONDAY, April 27, 2015 – A new class of cholesterol drug could sharply cut "bad" LDL cholesterol in people who don't fare well on commonly used cholesterol-lowering medications called statins, a new research review confirms. The drugs, known as PCSK9 inhibitors, are not on the market yet. But the U.S. Food and Drug Administration (FDA) is expected to decide later this year on the first two medications in the class: evolocumab (Repatha) and alirocumab (Praluent). The review of 24 clinical trials found that PCSK9 inhibitors lowered people's LDL cholesterol by about 47 percent, on average. More important, the drugs seemed to cut the risk of heart attack or death from heart disease, according to the researchers. Experts did urge some caution, however: Trials so far have been short-term, and it's not clear whether the new cholesterol drugs really do extend people's lives, according to Dr. ... Read more

Related support groups: High Cholesterol, Niacin, Niaspan, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Prevention of Cardiovascular Disease, Cardiovascular Risk Reduction, Slo-Niacin, Vascepa, Niaspan ER, Cardiovascular Conditions and Disorders, Nicotinic Acid, Choloxin, Niacin SR, Kynamro, Probucol, B-3-50, Niaspan ER Starter Pack, Icosapent Ethyl, Nicobid Tempules

Juxtapid Approved for LDL Cholesterol Condition

Posted 2 Jan 2013 by

WEDNESDAY, Jan. 2 – Juxtapid (lomitapide) has been approved by the U.S. Food and Drug Administration to treat a rare inherited disorder in which the body is unable to remove low-density lipoprotein (LDL) "bad" cholesterol from the blood. Homozygous familial hypercholesterolemia (HoFH) affects about 1 million people in the United States, the agency said in a news release. The inability to remove LDL cholesterol from the blood often causes heart attacks and death before age 30, the FDA said. Juxtapid, a once-daily capsule, is meant to be taken without food at least two hours before the evening meal, the agency said. The drug was evaluated in a clinical study of 29 people with HoFH, causing a drop in LDL levels of about 50 percent in 26 weeks among those who tolerated the treatment. The drug's label carries a boxed warning of the potential for serious liver poisoning and progressive liver ... Read more

Related support groups: High Cholesterol - Familial Homozygous, Juxtapid, Lomitapide

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol - Familial Homozygous, High Cholesterol

Juxtapid Patient Information at